Upadacitinib

Drug Profile

Upadacitinib

Alternative Names: ABT-494

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Atopic dermatitis; Crohn's disease

Most Recent Events

  • 11 Sep 2017 Positive top-line efficacy and adverse events data from the phase III SELECT-BEYOND trial in Rheumatoid arthritis released by AbbVie
  • 07 Sep 2017 Efficacy and adverse event data from a phase IIb trial in Atopic dermatitis released by Abbvie
  • 07 Sep 2017 Abbvie plans a phase III trial for Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top